1037 related articles for article (PubMed ID: 25394791)
101. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
102. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
103. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Ou SH
Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
[TBL] [Abstract][Full Text] [Related]
104. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
105. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
106. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
107. Therapeutics: Winning combination.
Villanueva MT
Nat Rev Cancer; 2015 Jan; 15(1):2. PubMed ID: 25533666
[No Abstract] [Full Text] [Related]
108. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
109. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
[TBL] [Abstract][Full Text] [Related]
110. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan D; Xu C; Yanagita M; Monast CS; Pratilas CA; Montero J; Butaney M; Shimamura T; Sholl L; Ivanova EV; Tadi M; Rogers A; Repellin C; Capelletti M; Maertens O; Goetz EM; Letai A; Garraway LA; Lazzara MJ; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2012 Oct; 2(10):934-47. PubMed ID: 22961667
[TBL] [Abstract][Full Text] [Related]
111. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
112. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
Camidge DR; Kono SA; Flacco A; Tan AC; Doebele RC; Zhou Q; Crino L; Franklin WA; Varella-Garcia M
Clin Cancer Res; 2010 Nov; 16(22):5581-90. PubMed ID: 21062932
[TBL] [Abstract][Full Text] [Related]
113. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
[TBL] [Abstract][Full Text] [Related]
114. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
[TBL] [Abstract][Full Text] [Related]
115. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
116. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
117. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
118. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
119. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
120. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
